9Tavadia SM,Mydlarski PR,Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol, 2000, 42:628-632.
1Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. New Engl J Med, 2003,348: 538-549.
2Roses AD. Pharmaeogenetics place in modem medical science and practice. Life Sci, 2002,70 : 1471-1480.
3Chen Z, Karaplis AC, Ackerman SL, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity with neuropathology and aortic lipid deposition . Hum Mol Genet,2001,10:433-443.
4Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reduetase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA, 1999,96:12810-12815.
5van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate recluctase gene: an additional risk factor for neural-tube defects. Am J Hum Genet, 1998,62 : 1044-1051.
6Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine,methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.Ann Rheum Dis, 1999,58:79-84.
7van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum, 2001,44:2525-2530.
8Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 2002,12:183-190.
9Krynetsld EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res, 1999,16: 342-349.
10McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics .Pharmacogenomics,2002,3 : 89-98.
5Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease-a 30 year review. Gut, 2002, 50: 485-489.
6Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res, 2003, 47: 1-10.
7Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol, 2003, 38: 740-746.
8Gaffney K, Scott DGI. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol, 1998, 37: 824- 836.
9Willkens RF, Sharp JT, Stablein D, et al. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. Arthritis Rheum, 1995, 38: 1799- 1806.
10Naughton MA, Bataglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology, 1999, 38: 640-644.
